Substituted indazole and aza-indazole derivatives as gamma secretase modulators
The present invention is concerned with novel substituted indazole and aza-indazole derivatives of Formula (I) wherein R 1 , R 2 , R 3 , R 4 , Y, A 1 , A 2 , A 3 , A 4 , X 1 , X 2 , X 3 and Het 1 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
1. A compound of formula (I)
or a stereoisomeric form thereof, wherein
R 1 is C 1-6 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyloxy, cycloC 3-7 alkyl, tetrahydropyranyl, tetrahydrofuranyl and phenyl; cycloC 3-7 alkyl; tetrahydropyranyl; tetrahydrofuranyl; 1,3-benzodioxolyl; or phenyl;
wherein each phenyl independently is optionally substituted with one or more substituents each independently selected from the group consisting of halo, cyano, C 1-4 alkyl optionally substituted with one or more halo substituents, and C 1-4 alkyloxy optionally substituted with one or more halo substituents;
R 2 is hydrogen; cyano; or C 1-4 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of C 1-4 alkyloxy, halo and NR 3 R 4 ;
X 1 is CH or N;
X 2 is CR 5 or N;
R 5 is hydrogen; halo; cyano; C 1-4 alkyloxy; or C 1-4 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyloxy and NR 3 R 4 ;
X 3 is CR 6 or N;
R 6 is hydrogen; halo; cyano; C 1-4 alkyloxy; or C 1-4 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyloxy and NR 3 R 4 ;
wherein each R 3 is independently hydrogen; C 1-4 alkyl; or C 1-4 acyl;
wherein each R 4 is independently hydrogen; C 1-4 alkyl; or C 1-4 acyl;
provided that no more than two of X 1 , X 2 and X 3 are N;
A 1 is CR 7 or N; wherein R 7 is hydrogen, halo or C 1-4 alkyloxy;
A 2 , A 3 and A 4 each independently are CH or N; provided that no more than two of A 1 , A 2 , A 3 and A 4 are N;
Het 1 is a 5-membered aromatic heterocycle, having formula (a-1), (a-2), (a-3) or (a-4)
R 8 is hydrogen or C 1-4 alkyl;
R 9 is hydrogen or C 1-4 alkyl;
R 10 is hydrogen or C 1-4 alkyl;
R 11 is hydrogen or C 1-4 alkyl;
R 12 is C 1-4 alkyl;
G 1 is O or S;
G 2 is CH or N;
or a pharmaceutically acceptable addition salt or a solvate thereof.
2. The compound according to claim 1 or a stereoisomeric form thereof, wherein
R 1 is C 1-6 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyloxy, cycloC 3-7 alkyl and phenyl;
cycloC 3-7 alkyl; tetrahydropyranyl; 1,3-benzodioxolyl; or phenyl;
wherein each phenyl independently is substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyl and C 1-4 alkyloxy;
R 2 is hydrogen; cyano; or C 1-4 alkyl optionally substituted with one or more NH 2 substituents;
X 2 is CR 5 or N; in particular X 2 is CR 5 ;
R 5 is hydrogen; halo; cyano; or C 1-4 alkyl optionally substituted with one or more NH 2 substituents;
X 3 is CH or N;
A 2 is CH or N, and A 3 and A 4 are CH;
Het 1 is a 5-membered aromatic heterocycle, having formula (a-1), (a-2), (a-3) or (a-4);
R 10 is C 1-4 alkyl;
R 11 is hydrogen;
R 8 is hydrogen;
R 12 is C 1-4 alkyl;
or a pharmaceutically acceptable addition salt or a solvate thereof.
3. The compound according to claim 1 or a stereoisomeric form thereof, wherein
R 1 is phenyl substituted with one C 1-4 alkyloxy substituent; or R 1 is C 1-6 alkyl substituted with one or more halo substituents;
R 2 is hydrogen;
X 1 , X 2 and X 3 are CH;
A 1 is CR 7 ; wherein R 7 is C 1-4 alkyloxy; A 2 , A 3 and A 4 are CH;
Het 1 has formula (a-1) or (a-2);
G 1 is O; G 2 is CH;
R 8 is C 1-4 alkyl;
R 10 is C 1-4 alkyl;
R 9 is hydrogen;
or a pharmaceutically acceptable addition salt or a solvate thereof.
4. The compound according to claim 1 , or a stereoisomeric form thereof, wherein
R 1 is phenyl substituted with one or more substituents each independently selected from the group consisting of C 1-4 alkyl and C 1-4 alkyloxy;
or a pharmaceutically acceptable addition salt or a solvate thereof.
5. The compound according to claim 1 , or a stereoisomeric form thereof, wherein
R 1 is C 1-6 alkyl optionally substituted with one or more halo substituents;
or a pharmaceutically acceptable addition salt or a solvate thereof.
6. The compound according to claim 1 wherein the compound is selected from the group comprising N-[3-methoxy-4-(2-methyl-5-oxazolyl)phenyl]-2-(2,2,2-trifluoroethyl)-2H-indazol-7-amine, and N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-(3-methoxyphenyl)-3-methyl-2H-indazol-7-amine,
including any stereochemically isomeric form thereof,
and the pharmaceutically acceptable addition salts and the solvates thereof.
7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as defined in any one of claims 1 to 6 .
8. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 6 and a pharmaceutically acceptable carrier.
9. A method for the treatment of a disease or condition selected from Alzheimer's disease, traumatic brain injury, mild cognitive impairment, senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, Down's syndrome, dementia associated with Parkinson's disease and dementia associated with beta-amyloid comprising administering to a subject a compound as defined in any one of claims 1 to 6 .
10. The method according to claim 9 wherein the disease is Alzheimer's disease.